AOD-9604
Last reviewed
Also known as: Advanced Obesity Drug 9604
AOD-9604 is a synthetic fragment of human growth hormone studied for its ability to burn fat without the blood sugar or growth side effects of full GH.
Mimics GH fat-burning domain. Stimulates lipolysis and inhibits lipogenesis by acting on beta-3 adrenergic receptors in fat tissue, without binding to the GH receptor.
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
§ AI Reference Summary
AOD-9604 (also known as Advanced Obesity Drug 9604) is a prominently researched experimental compound classified strictly within the GH Fragment framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it mimics GH fat-burning domain. Stimulates lipolysis and inhibits lipogenesis by acting on beta-3 adrenergic receptors in fat tissue, without binding to the GH receptor. with a documented biological half-life of roughly 1 hours, In preclinical investigative trials and independent academic studies, researchers utilizing AOD-9604 have documented significant, quantifiable biological outcomes, primarily focusing on fat loss without gh side effects. Typical research protocols investigate administering 300 to 300mcg via subq pathways 7x/wk. However, it is critically important to understand that while AOD-9604 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
§ Mechanism of Action
Mimics GH fat-burning domain. Stimulates lipolysis and inhibits lipogenesis by acting on beta-3 adrenergic receptors in fat tissue, without binding to the GH receptor.
§ Primary Benefits
- 1Fat loss without GH side effects
§ Clinical Evidence
AOD-9604 lipolysis stimulation in preclinical models
Ng et al. demonstrate AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue without affecting IGF-1 or glucose tolerance.
PreclinicalAOD-9604 clinical safety six randomized controlled trials
Heffernan et al.: Pooled analysis of 6 RCTs showing AOD-9604 is well-tolerated with a safety profile similar to placebo despite limited efficacy signals.
ModerateAOD-9604 Phase IIb trial short-term fat reduction
12-week Phase IIb trial: 1mg/day AOD-9604 produced 2.6 kg weight loss vs 0.8 kg placebo, with reductions in abdominal fat and improved lipid profiles.
ModerateSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
A 2026 review found that many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, though rigorous human safety data remain scarce. The study investigated the pharmacological mechanisms and regulatory status of various sports medicine peptides.
EmergingTherapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Therapeutic peptides such as BPC-157 and TB-500 were found to modulate key molecular pathways influencing tissue regeneration and inflammation resolution in a 2026 review. The study demonstrated that while preclinical mechanistic data is promising for orthopaedic applications, clinical trials remain lacking.
EmergingA novel inhibitor of pyruvate dehydrogenase kinase stimulates myocardial carbohydrate oxidation in diet-induced obesity.
A 2018 study in diet-induced obese mice demonstrated that PS10, a novel pyruvate dehydrogenase kinase inhibitor, stimulated myocardial carbohydrate oxidation and improved glucose tolerance. Researchers found that PS10 achieved these effects without increasing lactate production, unlike the classic inhibitor dichloroacetate.
PreclinicalSimplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.
A 2016 study demonstrated a highly sensitive screening method for detecting prohibited peptides under 2 kDa, such as GHRPs and TB-500, directly from urine. The liquid chromatography and mass spectrometry assay successfully identified peptide administration in human elimination samples, improving anti-doping control measures.
ModerateEffect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.
In a 2015 study, researchers found that intra-articular injections of AOD9604 enhanced cartilage regeneration in a rabbit model of osteoarthritis. Furthermore, the study demonstrated that combining AOD9604 with hyaluronic acid was more effective at reducing cartilage degeneration than either treatment alone.
PreclinicalHuman sports drug testing by mass spectrometry.
A 2017 review demonstrated that mass spectrometry has become an indispensable tool in modern sports drug testing. The paper detailed its critical role in detecting diverse substances, including peptidic drugs, anabolic agents, and nucleotide-derived therapeutics.
EmergingDetecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
A 2014 review found that advanced mass spectrometric and immunological methods can successfully detect the misuse of various peptidic drugs, including TB-500 and CJC-1295, in sports doping. However, researchers noted a gap remains between technical capabilities and routine analytical practice.
Emerging§ Safety Profile
Research-only. Received GRAS status from FDA as food supplement ingredient. Banned by WADA. Phase 3 trial discontinued due to insufficient efficacy.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
§ Dosing Protocol
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
RouteSubQ
Dose Range300–300 mcg
Frequency7x/wk
TimingMorning fasted
Cycle Length12–12 weeks
BAC Water2.5 ml / 5mg vial
Take on empty stomach. No effect on blood sugar or IGF-1.
§ Pharmacokinetics
⏱️ Half-Life: 1h
Plasma concentration over time§ Regulatory
🇺🇸USA
Research Only🇨🇦Canada
Research Only🇬🇧UK
Unregulated🇪🇺EU
Unregulated🇦🇺Australia
FDA/TGA ApprovedLast updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
§ Expected Outcomes
Weeks 2–4
Early lipolysis effects, especially in abdominal area
Month 2–3
Noticeable fat reduction in visceral stores; improved metabolic markers
Long-term
Sustained fat loss; may preserve muscle mass better than caloric restriction alone
§ Adverse Effects
| Side Effect | Incidence | Severity |
|---|---|---|
Injection site reaction | ~5% of users | mild |
Mild nausea | ~3% of users | mild |
Where to Source AOD-9604 for Research
Finding verified, high-purity AOD-9604 requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified AOD-9604✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Reconstitution CalculatorCalculate reconstitution for AOD-9604 →
Compare ToolCompare AOD-9604 to similar peptides →
Frequently Asked Questions
§ Comparisons
§ Community Stacks
Fat Loss Focus Stack
Maximum fat loss through targeted metabolic optimization and direct adipose tissue mobilization
Cite This Page
Free Download
2026 Peptide Stack Cheat Sheet
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
§ About the Author
Dr. E. Vance
Editorial Director, PeptiDex
Dr. E. Vance is the Editorial Director at PeptiDex and leads the platform's editorial division, ensuring that every published research summary meets rigorous preclinical citation standards. With a Ph.D. in Molecular Pharmacology from Columbia Univers...
View Full ProfileLast fact-checked: · PeptiDex Editorial Team
⚠ Educational only · Not medical advice · Most peptides are research-only / not FDA-approved